echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Express develops small molecule therapies targeting RNA, Xinwei receives 80 million US dollars in assistance

    Express develops small molecule therapies targeting RNA, Xinwei receives 80 million US dollars in assistance

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎Editor of WuXi AppTec's content team On September 29, 2021, Expansion Therapeutics announced the completion of a US$80 million Series B financing
    .

    The funds will be used to advance the small molecule drug platform (SMiRNA) targeting RNA to discover the treatment of myotonic muscular dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and more A drug candidate for tauopathies
    .

    A ribonuclease targeted chimera (RIBOTAC) technology developed by the company’s scientific founders can achieve targeted degradation of specific RNA
    .

     Expansion focuses on patients with neurological diseases that have few treatment options, such as DM1, a systemic disease that affects muscle, heart, and brain functions
    .

    Expansion focuses on RNA targets that are evolutionarily conserved or genetically proven to cause diseases and have three-dimensional structures
    .

    Expansion combines patient genetics with in-depth informatics analysis to identify those RNA structures that can bind to ligands, and then uses RNA-specific small molecule libraries to screen out small molecules that regulate the function of RNA targets
    .

    Subsequently, its new structural biology SMiRNA platform will be used to design and advance lead compounds, and ultimately provide an oral drug for the treatment of diseases
    .

    Expansion has also recently received licenses for two new research projects at the Scripps Institute, including a project for tau protein
    .

    Tau protein is an important driver of dementia
    .

    Studies have found that the abnormal mRNA precursor encoding tau protein is involved in the formation of neurofibrillary tangles and is associated with tau protein diseases (such as Alzheimer’s disease, frontotemporal dementia, progressive supranuclear palsy) and other neurodegenerative diseases Related
    .

    Image source: Expansion Therapeutics President and CEO Dr.
    Renato Skerlj said: “Small molecule drugs targeting RNA are expected to greatly change the lives of patients and treat serious RNA-mediated diseases, including neurodegenerative diseases and neurological diseases.

    .

    this financing milestone demonstrates investors' use of our proprietary technology platform to accelerate clinical confidence before new drugs and clinical development
    .

    "references: [1] Expansion Therapeutics Raises $ 80 Million Series B financing to Treat Neurodegenerative Diseases Retrieved September.
    29, 2021, from https:// Disclaimer: Medicine The content team of Mingkangde focuses on introducing the global biomedical health research progress
    .

    This article is for the purpose of information exchange only.
    The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
    .

    This article is not a treatment recommendation either
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.